Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MYC
REST API REST API
Homo sapiens
MYC is differentially expressed in 336 experiments: 146 organism parts: lung, hypothalamus, ... (144 more);, 173 disease states: normal, colon carcinoma, ... (171 more);, 107 cell types 388 cell lines 59 compound treatments and 73 other conditions.
Synonyms c-Myc, bHLHe39
Orthologs MYC_BOVIN (Bos taurus)   MYC_CHICK (Gallus gallus)   Bmyc (Mus musculus)   mycb (Danio rerio)   myca (Danio rerio)   Q4H361_CIOIN (Ciona intestinalis)   Bmyc (Rattus norvegicus)   myc (Xenopus laevis)   MYC_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, cell proliferation, transcription, DNA-dependent, positive regulation of cell proliferation, cell cycle arrest, spindle, nucleus, response to drug, cellular iron ion homeostasis, nucleoplasm, regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, nucleolus, positive regulation of mesenchymal cell proliferation, branching involved in ureteric bud morphogenesis, E-box binding, regulation of telomere maintenance, positive regulation of metanephric cap mesenchymal cell proliferation, sequence-specific DNA binding transcription factor activity
InterPro Term Tscrpt_reg_Myc, Myc-LZ, Tscrpt_reg_Myc_N, HLH_DNA-bd
UniProt Accession P01106, Q6LBK7, B0B0N9, B4E1N7, B3CJC0, B3CJC6, B3CJC7, B3CJC8, B3CJD6, B3CJD7, B3CJD5, B3CJD2, B3CJD3, B3CJD1, B3CJD8, B3CJD9, B3CJA1, B3CJA3, B3CJA4, B3CJA7, B3CJA9, B3CJB2, B3CJB3, B3CJB0, B3CJB1, B3CJB8, B3CJB9, B3CJE0, B3CJ82, B3CJ81, B3CJ88, B3CJ87, B3CJ86, B3CJ89, B3CJ91, B3CJ90, B3CJ93, B3CJ92, B3CJ94, B3CJ78, B3CJ77, B3CJ76, B3CJ71, B3CJ74, B3CJ75, B3CJ72, B3CJ73, B3CJ66, B3CJ65, B3CJ64, B3CJ69, B3CJ63, E5RGD7
Gene-Disease Assocation BURKITT LYMPHOMA; BL
Search EB-eye ENSG00000136997
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-GEOD-1577, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-GEOD-4717, ... (40 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
HL-60
1
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147, E-GEOD-96
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MDAMB175VII
2
E-MTAB-37, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
382 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-3920, E-MEXP-750, E-GEOD-2822, E-TABM-34, ... (55 experiments)

Factor Value U/D Experiments
CD4+ T cell
1
3
E-AFMX-5, E-GEOD-16190, E-MEXP-1600, E-GEOD-6740
2
E-TABM-145, E-TABM-130
CD34+
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
CD8+ T cell
2
E-AFMX-5, E-GEOD-6740
skin substitute
1
E-GEOD-3204
101 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (63 experiments)

Factor Value U/D Experiments
glioblastoma
4
E-MTAB-37, E-GEOD-6014, E-MEXP-567, E-GEOD-4290
colon carcinoma
4
E-MTAB-62, E-GEOD-3726, E-MTAB-57, E-MTAB-37
control
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-20602
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-1880
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
167 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-697, E-GEOD-5824, ... (45 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-TABM-868, E-MEXP-1958, E-GEOD-3720
glutamine
2
E-MEXP-941, E-MEXP-1335
dimethyl sulfoxide
2
E-GEOD-6932, E-GEOD-5824
control
1
2
E-GEOD-995, E-GEOD-4006, E-GEOD-5339
BCR/ABL1
1
E-GEOD-15811
n/a
1
E-MEXP-2449
53 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-1140, E-GEOD-860, ... (11 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-MEXP-2359, E-MEXP-958, E-MTAB-62 ... (5 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-GEOD-1923, E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-TABM-127, E-MEXP-1446, E-GEOD-22278, ... (12 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-1926, E-GEOD-3606, ... (31 experiments)

Infection
studied in E-GEOD-697, E-MEXP-1274, E-GEOD-9723, E-GEOD-6927, E-MEXP-561, ... (7 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-26495, E-GEOD-19703, E-GEOD-1309, E-GEOD-1493, ... (10 experiments)

Population
studied in E-MTAB-197

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-1703, E-GEOD-1676, E-MEXP-548, E-GEOD-3697, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7540, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-22152, E-GEOD-19815, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.48 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM